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Abstract
Meningiomas are the most common primary nervous system tumor. The tumor suppressor NF2 is
disrupted in approximately half of meningiomas1 but the complete spectrum of genetic changes
remains undefined. We performed whole-genome or whole-exome sequencing on 17 meningiomas
and focused sequencing on an additional 48 tumors to identify and validate somatic genetic
alterations. Most meningiomas exhibited simple genomes, with fewer mutations, rearrangements,
and copy-number alterations than reported in other adult tumors. However, several meningiomas
harbored more complex patterns of copy-number changes and rearrangements including one tumor
with chromothripsis. We confirmed focal NF2 inactivation in 43% of tumors and found alterations
in epigenetic modifiers among an additional 8% of tumors. A subset of meningiomas lacking NF2
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alterations harbored recurrent oncogenic mutations in AKT1 (E17K) and SMO (W535L) and
exhibited immunohistochemical evidence of activation of their pathways. These mutations were
present in therapeutically challenging tumors of the skull base and higher grade. These results
begin to define the spectrum of genetic alterations in meningiomas and identify potential
therapeutic targets.
Meningiomas, tumors that arise from arachnoidal cap cells of the leptomeninges, constitute
approximately one-third of primary central nervous system (CNS) tumors1. Most
meningiomas (80%) are World Health Organization (WHO) grade I and treated by surgical
resection. However, resection of some meningiomas, particularly at the skull base, is
associated with high morbidity. Moreover, 18% of these will recur within five years, and
patients with grade I tumors have significantly reduced long-term survival related to both
tumor recurrence and stroke risk2. Recurrence rates for grade II and III meningiomas can be
as high as 40% and 80%, with 5-year overall survival of approximately 76% and 32%,
respectively1,3,4. Although there are recent reports of a stepwise progression of a subset of
grade I meningiomas to higher grades5,6, these secondary grade II/III meningiomas may
differ fundamentally from spontaneously arising grade II/III tumors. Radiation is frequently
used as an adjunct to surgery; however, there are no effective chemotherapeutic options
when surgery and radiation fail to offer durable long-term disease control7.
We sequenced DNA from a discovery set of grade I meningiomas using whole-genome (n =
11) and whole-exome (n = 6) techniques to identify somatic copy-number alterations
(SCNAs), rearrangements, mutations, and insertions/deletions throughout the genome. We
then sequenced 645 known cancer-associated genes, including genes altered in this
discovery set, in a validation set of 30 additional grade I tumors. We also sequenced these
genes in an extrapolation set of 18 grade II-III meningiomas to evaluate whether findings in
grade I tumors extended to the tumors of higher grades (Online Methods, Supplementary
Tables 1 and 2).
Meningiomas in the discovery set exhibited a small number of somatic genetic events
compared to other tumor types8–14. We sequenced to high depth (median 57X genome,
181X exome, and 154X validation/extrapolation coverage) and utilized large-insert libraries
in whole-genome samples (500 bp and 800 bp) to optimize our detection of rearrangements
and other events. Nevertheless, we found that the median meningioma exhibited SCNAs
affecting only 3.3% of the genome, one rearrangement, and 8 non-synonymous mutations.
Among mutations, cytosine to thymidine transitions within a CpG context predominated,
consistent with spontaneous deamination (Supplementary Fig. 1a)15. The rates of alteration
we observed in meningiomas were significantly lower (often by a factor of 10 or more) than
previously determined rates for other tumors that have been sequenced to lower depth and
with smaller insert sizes (Fig. 1a–c). These findings may reflect differences in mitotic index,
prior treatments, or carcinogen exposure between these tumor types.
In contrast, rates of genomic disruption were higher among the grade II-III meningiomas in
the extrapolation set than their grade I counterparts (Supplementary Fig. 2). The mean rate
of non-synonymous mutations within the 645 sequenced genes was nearly twice as high in
higher-grade tumors (3.0 vs. 1.6; p<0.02), and the proportion of the genome affected by
SCNAs was dramatically higher (median 12.8 vs. 0.3%; p<0.001).
Among SCNAs, loss of chromosome 22 (containing NF2) was the most frequent genetic
alteration in the discovery cohort, occurring in all 10 tumors with focal NF2 alteration
(defined as mutation, insertion/deletion, or rearrangement within the NF2 locus) and one
without (Fig. 1d, Supplementary Fig. 3). The association between NF2 mutation and chr22
loss extended to the validation and extrapolation sets (p<0.0001) and confirms prior reports
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using other methods16. In the grade I tumors, we also found recurrent significant losses on
1p, 7p, 14p, and 19 and gains on chr5 and chr20 (q<0.1), some of which have been
described previously17. Higher-grade tumors of the extrapolation set exhibited additional
recurrent losses on 10q and 14q, previously reported in atypical and anaplastic
meningiomas1. We did not observe previously described losses of DAL-1, a gene related to
NF2 on 18p18.
We identified a total of 110 candidate somatic rearrangements in whole-genome samples, of
which 93 were confirmed to have reads spanning the putative fusion site (Supplementary
Table 3, Supplementary Fig. 4). Most of these were concentrated in three tumors (Fig. 2),
one of which exhibited chromothripsis, a simultaneous rearrangement of one or more
chromosomes estimated to occur in 2–3% of aggressive malignancies19,20. One of the genes
disrupted by chromothripsis was the putative tumor suppressor NEGR1, which was also
rearranged in a second tumor. NEGR1 plays a role in CNS development and is recurrently
deleted in neuroblastoma21, though its role in tumorigenesis remains to be elucidated. A
third sample harbored disruptions in the known and putative tumor suppressors NF1, NF2,
and CDK14. A copy-neutral 12.5Mb inversion caused reciprocal fusion of NF2 (before exon
2) and TCF20, representing a novel mechanism of inactivating NF2 in meningiomas. We
also identified other translocations in samples that were not subjected to whole-genome
analysis, including a truncating translocation in CHEK2 (Supplementary Fig. 4i and
Supplementary Table 3). The loss of CHEK2 may lead to impaired DNA repair, as has been
described in meningioma cell lines22.
The most frequently mutated gene was NF2, which exhibited a total of nine nonsense
mutations, nine splice site mutations, nine frame-shift insertions-deletions, and the above-
mentioned translocation (Supplementary Fig. 5). The majority of these events overlap with
previously reported events, and our rates of NF2 inactivation are consistent with published
rates1. The non-synonymous mutation rates of tumors with and without focal NF2
alterations did not differ significantly, nor did the spectra of their mutation subtypes
(Supplementary Fig. 1b–d).
We also identified non-synonymous mutations in 190 other genes (Supplementary Tables 4
and 5). We determined the significance of mutation rates in individual genes relative to
genome-wide background rates. Six genes reached statistical significance (Fig. 3,
Supplementary Fig. 5, Supplementary Table 4). Four of these (NF2, KDM5C, SMO, and
AKT1) have previously been implicated in cancer, and the other two (RGPD3 and CD300C)
have not. Isolated or rare mutations that did not reach significance across the entire cohort
were observed in 23 genes with known involvement in cancer, including TP53, APC, CBL,
STK11 and NOTCH2.
Among genes mutated in our cohort and previously associated with cancer, three (KDM5C,
KDM6A, and SMARCB1) are epigenetic modifiers. Mutations involving these genes
affected 8% of the cohort. Both KDM5C (also known as JARID1C) and KDM6A are
histone demethylases23; SMARCB1 (also named SNF5 and INI1) is a member of the SWI/
SNF chromatin-remodeling complex. SMARCB1 is located 6 Mb from NF2, and a “four
hit” model of biallelic inactivation of both genes has been described in familial
schwannomas24. The mutation we identified (R374Q) is near a mutational hotspot (R377H)
described in meningiomas25 and germline mutations in SMARCB1, including R374Q, have
been reported in the congenital disorder, Coffin-Siris syndrome26.
We observed mutations of SMO, a member of the Hedgehog (Hh) signaling pathway, in
three tumors (5%). None of these tumors exhibited focal alterations of NF2. Two samples
harbored SMO W535L, a known oncogenic mutation in basal cell carcinomas27, and a third
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harbored an L412F mutation, previously reported in desmoplastic medulloblastoma28. The
allelic fractions of these mutations (45%, 55% and 47%) were among the highest in these
tumors, suggesting clonality. Moreover, dysregulation of the Hh pathway has been
previously described in meningiomas29,30. Gorlin syndrome (nevoid basal-cell carcinoma
syndrome) is caused by a germline PTCH1 mutation (upstream of SMO), and is
characterized by predisposition to multiple cancers, including desmoplastic
medulloblastomas and meningiomas31,32. Although we did not observe somatic mutations in
PTCH1, two samples harbored germline alterations that were also present in the tumor
(D436N, E44G/P1282L). However, these patients did not exhibit manifestations of Gorlin
syndrome, so the functional significance of these specific events is unclear.
Six samples exhibited mutations of the PI3K/AKT/mTOR pathway. None of these had
mutations of NF2 or SMO (p=0.03). Five samples harbored identical AKT1 mutations
(E17K) known to be oncogenic in breast, colorectal and lung cancers33. The E to K
substitution results in constitutive AKT1 activation, which stimulates downstream mTOR
signaling. The sixth sample exhibited a novel MTOR mutation (D1279V).
The Hh and PI3K pathway mutations were also associated with particular histopathologic
subtypes (Fig. 4). SMO- and AKT1/MTOR- mutated meningiomas were predominantly of
the meningothelial subtype (p=0.009, p=0.005, Fisher’s exact test). This is in contrast to the
grade I NF2-altered tumors, which were predominantly fibroblastic and/or transitional
(p=0.013), consistent with prior reports34. We did not find statistically significant
correlations with other clinically relevant variables including age, location or prior resection.
However, one AKT1- and two SMO-mutated tumors were resected from the skull base, a
region that offers particular challenges to resection and higher rate of recurrence35
(Supplementary Table 5).
To validate these findings, we also genotyped an additional 46 grade I and 49 grade II/III
meningiomas for AKT1 (E17K) and SMO (W535L and L412F) mutations using a mass
spectrometric based method (Sequenom hME). We found one SMO (L412F) mutation and
three additional AKT1 (E17K) mutations (Supplementary Table 6). One of these was in a
grade III tumor, and the remaining three were in skull base tumors, of which two were of
meningothelial histology.
Mutations in SMO, AKT1, and MTOR also correlated with markers of pathway activation.
GAB1 immunoreactivity is used in medulloblastomas to characterize tumors with Hh
pathway activation36. Among the 65 meningiomas, seven exhibited strong immunoreactivity
for GAB1, including the three tumors harboring SMO mutations (p=0.0008). The other four
GAB1-positive tumors were grade II meningiomas. Likewise, STMN1 expression is a
marker of PI3K/Akt pathway activation37. Ten meningiomas exhibited strong STMN1
expression, including all six AKT1 and MTOR-mutated meningiomas (p=3×10−6). Notably,
all three SMO-mutated meningiomas also exhibited strong (n=2) or moderate (1) STMN1
staining. This is consistent with studies that have suggested that Hh and PI3K/AKT/mTOR
pathways may interact38.
We observed recurrent mutations in signaling pathways and epigenetic modifiers, but our
data also highlight the heterogeneity of mutations in these tumors. Among the 17 tumors we
comprehensively characterized, three (18%) did not exhibit mutations in any of the
significantly mutated genes. Genomic characterization of additional tumors, particularly of
higher grades, is likely to reveal additional oncogenic mechanisms.
These observations also have the potential to guide new therapeutic strategies. We observed
SMO and AKT1 mutations in tumors that pose special therapeutic challenges, including a
high-grade and six skull-base tumors. Inhibitors of SMO have generated high response rates
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in patients with basal cell carcinoma, many of which are driven by Hh pathway mutations39.
Likewise, inhibitors of the PI3K/AKT/mTOR pathway have shown promise in preclinical
and clinical trials in multiple cancer types40. The paucity of additional genetic events in
meningiomas harboring mutations of PI3K and Hh signaling pathways suggests that patients
with these meningiomas may benefit from such targeted therapies already in development or
use.
ONLINE METHODS
Sample Selection and Preparation
This study was reviewed and approved by the human subjects institutional review boards of
the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and the Broad Institute
of Harvard and MIT. Written informed consent was obtained from all participants. We chose
to initially perform whole-exome sequencing in 6 meningiomas as a pilot study to determine
the optimal depth of whole-genome sequencing needed to provide adequate tumor coverage
in spite of stromal contamination. These six tumors and 11 additional whole-genome
sequenced meningiomas comprised the discovery cohort. To validate clinically actionable
mutations identified in the discovery set, we performed focused sequencing on a validation
cohort consisting of an additional 30 grade I meningiomas. We also assembled an
extrapolation cohort of 15 grade II and 3 grade III meningiomas (Supplementary Table 1) in
order to compare genetic aberrations of low- and high-grade tumors. Our approach of deep,
broad sequencing of a small representative cohort followed by validation in an independent
larger group is similar to the approach used by others to discover IDH141 and PIK3CA42
mutations. Three study pathologists (SS/DL/ASR) reviewed the histopathologic diagnosis,
grade and purity of each tumor.
Representative fresh-frozen blocks with estimated purity of ≥90% were selected. DNA was
extracted from tissue shavings and buffy coat preparations of paired blood using standard
techniques (QIAGEN, Valencia CA) then quantified using PicoGreen® dye (InVitrogen,
Carlsbad CA). Identities of tumor-normal pairs were confirmed by mass spectrometric
genotyping using a well-established 48-SNP panel (Sequenom, San Diego CA)43.
Data, including sequence data and analyses, are available for download via dbGaP (http://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000552.v1.p1).
Sequencing
For whole-genome sequencing (n=11), DNA was randomly fragmented and libraries of two
insert sizes were prepared (500 and 800bp) for paired-end sequencing on Illumina HiSeq
200010,11. Target depth (60X-tumor/30X-normal) was achieved in all but one sample
(MEN0015) that failed 800bp library preparation; however, adequate coverage of the 500bp
library was achieved.
For whole-exome sequencing (n=6), 250bp libraries were prepared by Covaris sonication
(Covaris, Woburn MA), followed by double size-selection (Agencourt AMPure XP beads)
and ligation to specific barcoded adaptors (Illumina TruSeq) for multiplexed analysis.
Exome hybrid capture was performed with NimbleGen SeqCap EZ Exome Library SR v2.2,
Agilent Sure Select All Exon v2.0 hybrid capture kit, or both approaches. All samples but
one achieved >150X coverage in exon regions (MENex004, 79X-tumor/90X-normal).
We proceeded with sequencing 645 cancer-associated genes in our larger validation and
extrapolation sample set (n=48) because this pre-selected gene set (OncoPanel) included all
genes of interest that were also clinically actionable (including AKT and SMO) that arose in
the discovery set. In addition, a wide breadth of other genes in the same families (such as
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MTOR in the AKT pathway) and other interesting cancer-related genes in other families
were included (Supplementary Table 2). Briefly, DNA was sonicated to achieve an average
fragment size of 150bp, then size-selected and barcoded as above. Each multiplexed pool
was hybridized with biotinylated baits (Agilent SureSelect, Agilent) designed to capture
exonic sequences. Streptavidin-coated beads were used to pull down the complexes, which
were loaded on a HiSeq2000 for paired-end sequencing.
Sequencing Analysis Pipeline
For exome- and OncoPanel-sequenced data, pooled sample reads were de-multiplexed using
Picard tools (http://picard.sourceforge.net). Read pairs were aligned to the hg19 reference
sequence (b37) (ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/technical/reference/) using the
Burrows-Wheeler Aligner44 (http://bio-bwa.sourceforge.net/bwa.shtml) with options: -q 5 -l
32 -k 2 -o 1. Data were sorted and duplicate-marked using Samtools (http://
samtools.sourceforge.net) and Picard. Bias in base quality score assignments due to flowcell,
lane, dinucleotide context, and machine cycle were analyzed and recalibrated, and local
realignment around insertions/deletions was achieved using the Genome Analysis Toolkit
(GATK) (http://www.broadinstitute.org/gatk/)45,46.
Variant and germline calling were performed within the Firehose environment11 using
GenePattern47. All algorithms described are available publicly (https://
confluence.broadinstitute.org/display/CGATools). All sample pairs passed a QC pipeline to
test for any tumor/normal and inter-individual mix-ups by comparing insert-size distribution
and copy-number profile as described previously10. The Mann-Whitney test was used to
determine significance of differences between rates of somatic genetic alteration between
meningiomas and the other datasets.
Somatic copy-number alterations (SCNAs) and rearrangements
SCNAs were evaluated using SegSeq48, which uses a combination of local change-point
analysis and subsequent merging of adjacent chromosomal segments with similar copy-
number. For arm-level significance analysis, pseudo-markers were added every 10,000 bases
to segmented copy-number data, and these were analyzed by GISTIC 2.0 to determine
which events occurred more often than expected by chance14.
Rearrangements and their exact breakpoints were identified using the combination of
dRanger and BreakPointer algorithms8,10. Briefly, dRanger identifies potential
rearrangements from read pairs mapping to different chromosomes or unexpected positions /
orientations on the same chromosome, and BreakPointer locates reads spanning the fusion
and maps the exact breakpoint using modified Smith-Waterman alignment10.
Rearrangements are assigned a score reflecting the number of tumor reads supporting a
breakpoint, the fraction of nearby reads with MAPQ0, the prevalence of other nearby
discordant pairs, and the standard deviation of breakpoint starting positions. To minimize
false-positive rearrangements, only breakpoints with score ≥8 passing BreakPointer were
accepted. The specificity of this type of approach has previously been shown to be >90%10.
Copy-number and rearrangement results were displayed using the Circos program (http://
mkweb.bcgsc.ca/circos)49.
Identification of base pair substitutions and short insertion-deletions
Mutations were only considered at covered positions (≥8X-normal and 14X-tumor sites).
Somatic mutations and short insertions/deletions were called and post-filtered using MuTect
and IndelLocator10,11. These were annotated to genes and compared to events in the
Catalogue of Somatic Mutations in Cancer (COSMIC) using Oncotator, and spurious calls
caused by mis-mapping and other previously identified systematic errors were removed
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using an established list of known problematic sites11–13. MutSig was used to determine the
significance of mutated genes, adjusting for cohort- and genome-wide mutation rate, local
background mutation rate, and gene length11–13. We used a cohort-wide background
mutation rate instead of the more commonly used sample-specific mutation rate because the
observed low mutation rate in these tumors leads to poor sampling of individual mutation
subcategories. This may lead to overly large apparent variations between background rates
of mutation subtypes in different samples. Mutations are shown in the context of UniProt
regions and domains (www.uniprot.org). Post-hoc analyses for significant non-overlap of
NF2, SMO, and AKT1 mutations were determined by Fisher’s exact test, as were
associations between these mutations and chr22 loss or specific categorical demographic
characteristics. The Mann-Whitney test was used for comparisons of mutations and
continuous demographic variables.
Germline variants were called using UnifiedGenotyper45,46, filtered against the
1000genomes dataset50, and annotated to genes as above. Genes with known syndromic
associations to meningiomas (NF1, NF2, SMARCB1 and PTCH1) were manually reviewed
for germline non-synonymous mutations. These were visualized in Integrative Genomics
Viewer (www.broadinstitute.org/igv/).
Sequenom Validation
We obtained IRB approval for collection of independent archival paraffin-embedded
meningioma samples from the Brigham and Women’s Hospital Pathology Department. We
identified 95 samples from patients that did not overlap with our cohort of 65 tumors,
resected between 2005 and 2012. Forty-nine of these were higher-grade meningiomas.
Tissue was de-paraffinized and DNA extracted using standard techniques (QIAGEN,
Valencia CA). Variants in SMO (W535L and L412F) and AKT1 (E17K) were assayed using
Sequenom’s homogeneous Mass-Extend (hME) Genotyping system (Sequenom, Inc. San
Diego, CA). Bidirectional probes and primers were designed using Sequenom MassARRAY
Typer software (v 4.0), and hME genotyping was performed using 5ng of unamplified
genomic DNA template per assay pool (maximum of 4 assays per pool).
Immunohistochemistry
Tissue sections were deparaffinized and rehydrated using Xylene and graded alcohols.
Endogenous peroxidase activity was blocked with 3% H2O2 in 100% ethanol (1:1; 15
minutes). Antigen retrieval was performed with Dako Target Retrieval Solution, pH 6.0 and
pressure cooker treatment (120+/−2°C, 15+/−5 psi) for 45 seconds. Sections were incubated
with primary antibodies against GAB1 (Abcam ab27439, 1:100×45min), Ki67 (Vector Lab
VP-451, 1:2500×45min), or Stathmin (Cell Signaling Technologies #3352, 1:120,
4°C×16hr), followed by secondary antibody (Dako Labeled Polymer-HRP anti-rabbit IgG
x30min). Visualization was with 3,3'-diaminobenzidine as a chromogen (Envision+System)
and Gill hematoxylin counterstaining. Associations between specific mutations and their
differences in histopathological subtypes and immunohistochemical staining were
determined post-hoc with Fisher’s exact test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
The landscape of somatic alterations in the grade I meningioma genome. (a) Fraction of the
genome altered by somatic copy-number alterations (SCNAs), (b) number of somatic intra-
and inter-chromosomal rearrangements, and (c) number of non-synonymous mutations in
meningiomas and other tumor types. MEN: meningioma; PR: prostate; CRC: colorectal
carcinoma; BCL: diffuse large B-cell lymphoma; MEL: melanoma; MM: multiple myeloma;
HN: head and neck cancers. (d) Somatic genetic alterations in individual grade I
meningiomas of the discovery cohort. Top: Copy-number profiles (red = gain, blue = loss).
Middle: Number of somatic rearrangements per tumor. Samples labeled as MENex are
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exome-sequenced, in which no rearrangements were detected. Bottom: Total non-
synonymous and synonymous mutations in exons. ** p<0.01, *** p<0.0001.
Brastianos et al. Page 12
Nat Genet. Author manuscript; available in PMC 2013 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Somatic rearrangements disrupt tumor suppressors in several meningiomas. Circos plots
show the SCNAs (inner ring heat map) and intra- and inter-chromosomal rearrangements
(green and purple arcs, respectively) in three whole-genome sequenced meningiomas. Left:
Chromothripsis of chromosome 1 (enlarged in inset) in an NF2-mutated sample (MEN0017)
disrupts the putative tumor suppressor NEGR1. Middle: A second NF2-mutated sample
(MEN0018) harbors 29 rearrangements including disruption of NEGR1. Right: An inversion
on chromosome 22 disrupts NF2, and other rearrangements affect NF1 and CDK14
(MEN0009). Data from the remaining tumors are shown in Supplementary Figure 4.
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Figure 3.
Significant and selected cancer-related somatic mutations, insertion-deletions, and
translocations in meningiomas. Mutation subtypes are denoted by the indicated colors. If
multiple mutations were found in a gene in a single sample, only one is shown. Discovery
set tumors are in the same order as in Figure 1d. Right: Significance of mutations in each
gene, as false discovery rate q-values. The full list of mutated genes is shown in
Supplementary Table 4.
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Figure 4.
Associations between mutations in Hh and Akt/mTOR pathways and histologic findings. (a)
AKT/MTOR and SMO-mutated samples are predominantly of the meningothelial subtype
(p=0.009, p=0.005). NF2-mutated samples are predominantly fibroblastic and transitional
(p=0.013). (b) Immunohistochemistry indicates activation of Hh and Akt/mTOR pathways
in tumors harboring SMO and AKT1 mutations, respectively (p=0.0008, p=3×10−6). GAB1
staining was used as a marker of Hh pathway activation, and STMN1 staining was used as a
marker of PI3K/Akt/mTOR pathway activation. Scale bars denote 50 micrometers.
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